Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Details : Novel rAd-IFN/Syn3 intravesical gene therapy given once every three months studied in patients with high-grade, BCG-unresponsive non-muscle invasive bladder cancer.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
November 30, 2020
FerGene to Present Bladder Cancer Data at 2020 ASCO
Details : Data highlight a need for bladder-sparing therapies to improve outcomes for patients with high-grade, non-muscle invasive bladder cancer.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
October 02, 2020